jeudi 29 mars 2018

Onco Actu du 29 mars 2018

1. Biologie

Aggressive Growth of Common Brain Tumors Linked to Single Gene [UCSF]

Newly discovered organ may aid in cancer diagnosis [CNBC]

3.1 Prévention - Tabac

FDA Commissioner Says Enforcement Power Could Be Used In Right-To-Try, E-Cigarrettes [Forbes]

Help people make informed decisions when they want to quit smoking, says NICE and Public Health England. [NICE]

3.1.1 Prévention - Tabac - e-cigs

Doctors should advise smokers on using e-cigarettes, says NICE [BMJ]

4.2 Dép., diag. & prono. - Génome

Study Finds Inaccuracies in 40 Percent of DTC Genetic Testing Results [The Scientist]

4.5 Dép., diag. & prono. - Colorectal

Colon cancer screening rates vary widely across U.S. [Reuters]

4.7 Dép., diag. & prono. - Col de l'utérus

New data suggests cervical cancer screening guidelines need to be reconsidered [SGO]

4.9 Dép., diag. & prono. - Sein

Marketing misfire on ‘spa-like’ 3D mammograms: Comfort appeal distracts from real concerns on screening, experts say [HealthNewsReview]

5.1 Traitements - Pré-clinique

'Virtual tumours' predict success of tumour-heating sound waves [Institute of Cancer Research]

5.10 Traitements - Essais

Clinical trials take a long time to get started. Here’s how to speed it up [STAT]

Colon cancer chemo could be halved after surgery [Cancer Research UK]

NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomas [NCI]

5.12.2 Immunothérapies - CAR-T

How Treatment Works for CAR T-Cell Therapy Patients [Dana-Farber Cancer Institute]

Bluebird, Celgene to share U.S. costs, profits on lead cancer CAR-T [FierceBiotech]

bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States [bluebird bio]

Bluebird whistles up a co-development/co-promotion pact with Celgene on bb2121 CAR-T [EndPoints]

5.12.8 Immunothérapies - Economie

Tempest Therapeutics launch shows IDO inhibitors are still hot [C&EN]

Versant-backed Tempest grabs a $70M round with plans to drive a slate of I/O drugs into the clinic [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Shire Put in Play [Bloomberg]

Does a $50B-plus Shire buyout even make sense for Takeda? Maybe not [EndPoints]

Shire Surges on News of Possible Takeda Bid [Bloomberg]

Takeda Statement Regarding Shire plc [Takeda]

5.4 Traitements - Economie

Final NICE green light for Ipsen’s Cometriq [PharmaTimes]

In bid to lower prices, Gottlieb says FDA will take new action to speed approval of biosimilars [STAT]

6. Lutte contre les cancers

Last Month in Oncology with Dr. Bishal Gyawali: February 2018 [ecancernews]

6.1 Observation

Childhood cancer survivors may develop heart problems sooner [Reuters]

6.11 Patients

The people that make radiotherapy possible: Part 2 – clinical trial patients [Cancer Research UK]